14-day reverse hybrid therapy vs 7-day concomitant therapy in the first-line treatment of Helicobacter pylori infection

被引：3

作者：

Chang, Shiuh-Nan ^{[1
]}

Shih, Yung-Hsiung ^{[1
]}

Lee, Wen-Ching ^{[1
]}

Kuo, Ming-Te ^{[1
]}

Tsay, Feng-Woei ^{[2
]}

Kuo, Li-Fu ^{[3
]}

Huang, Wen-Wei ^{[3
]}

Shie, Chang-Bih ^{[3
]}

机构：

[1] Jiu Da Union Clin, Kaohsiung, Taiwan

[2] Natl Yang Ming Univ, Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kaohsiung, Taiwan

[3] China Med Univ, An Nan Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, 66,Sect 2,Changhe Rd, Tainan 709204, Taiwan

来源：

ADVANCES IN DIGESTIVE MEDICINE | 2022年 / 9卷 / 01期

关键词：

concomitant therapy; Helicobacter pylori; reverse hybrid therapy; TRIPLE THERAPY; METAANALYSIS;

D O I：

10.1002/aid2.13243

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Increasing antibiotics resistance poses a great challenge for the treatment of Helicobacter pylori (H. pylori) infection. The reported eradication rates of 7-day standard triple therapy have fallen below 80% in most countries due to increasing clarithromycin resistance. Both 14-day reverse hybrid therapy and 7-day concomitant therapy have been reported to yield high eradication rates for the treatment of H. pylori infection. However, whether 14-day reverse hybrid therapy can achieve a higher eradication rate than 7-day concomitant therapy remains unanswered. The aim of this study is to compare the efficacies of 14-day reverse hybrid and 7-day concomitant therapies for the first-line treatment of H. pylori infection in a primary care setting. From May 2016 to December 2019, 322 H. pylori-infected patients receiving either 14-day reverse hybrid therapy (a proton pump inhibitor [PPI] plus amoxicillin 1 g b.d. for 14 days, and clarithromycin 500 mg plus metronidazole 500 mg b.d. for the initial 7 days, n = 142) or 7-day concomitant therapy (PPI plus amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg b.d. for 7 days, n = 180) in our clinic were included in the retrospective study. All the patients underwent a follow-up endoscopy with a rapid urease test or a urea breath test at least 4 weeks after completion of anti-H. pylori therapy and at least 2 weeks after discontinuation of PPI. Intention-to-treat analysis demonstrated a significantly higher eradication rate for the 14-day reverse hybrid group than for the 7-day concomitant group (95.8% vs 88.9%, P = .024). Per-protocol analysis also yielded similar results (97.8% vs 90.3%, P = .009). Both groups had similar frequencies of adverse events (14.1% vs 13.9%, P = .990) and drug compliance (95.8% vs 97.2%, P = .478). Conclusions Fourteen-day reverse hybrid therapy achieves a higher eradication rate than 7-day concomitant therapy in the first-line treatment of H. pylori infection.

引用

页码：38 / 43

页数：6

共 26 条

[1]

[Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1

[2] Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia [J].